AFFILIATIONS
1 Aflac Cancer & Blood Disorders Center - Emory University, Atlanta, Georgia, United States
2 HZRM Hämöphilie-Zentrum Rhein Main, Frankfurt, Germany
ABSTRACT
Introduction: Factor VIII (FVIII) inhibitor development is a serious treatment-related complication in patients with hemophilia A (HA), rendering FVIII therapy ineffective. While emicizumab is approved to prevent bleeding in patients with and without inhibitors, therapy with FVIII concentrates is still required for acute bleeding control and surgical prophylaxis. Immune tolerance induction (ITI) therapy, the intensive repeated administration of FVIII, is the only clinically proven strategy to eliminate inhibitors. MOTIVATE (NCT04023019; EudraCT 2019-003427-38) is an investigator-initiated, international, multicenter, non-randomized, prospective study of real-world management of patients with HA and inhibitors. It aims to evaluate the efficacy and safety of ITI, emicizumab prophylaxis, and ITI with emicizumab prophylaxis. Here, we report additional findings from the second interim analysis.
Methods: Male patients of any age with HA and FVIII inhibitors, with or without previous unsuccessful ITI attempts, were eligible. Treatment was at the investigator’s discretion. Based on treatment approach, patients were assigned to: Group 1, ITI (FVIII only); Group 2, ITI and emicizumab prophylaxis; or Group 3, emicizumab prophylaxis without ITI. Activated prothrombin complex concentrates (aPCC) or recombinant FVIIa could be used for bleed treatment or surgical prophylaxis in all groups. Analyses were based on exposure-defined observation periods. Participants contributed data to treatment groups according to their treatment protocol at time of assessment. Because participants could change treatment protocols during the study, an individual participant could contribute data to more than one group across different observation periods. For ITI outcomes, patients were assigned to the group in which the first inhibitor titer result was <0.6 Bethesda units (BU)/mL, if not met then to that with the longest ITI duration.
The primary outcome for Groups 1 and 2 was a comparison of ITI outcomes as determined by the proportion of participants achieving: FVIII inhibitor titer <0.6 BU/mL, FVIII recovery ≥66% of normal, and FVIII half-life ≥6 hours (or FVIII trough level >1% if half-life not available). The primary outcome for Group 3 was the annualized bleeding rate (ABR) compared to the ABR in Groups 1 and 2. Secondary outcome measures included time to achieve ITI outcomes and frequency and severity of bleeding events (BEs). Safety was assessed based on the incidence of adverse drug reactions (ADRs).
Results: As of February 2026, 66 patients were eligible for inclusion in this second interim analysis. Overall, 15 patients switched treatment groups; some patients switched multiple times, resulting in n = 15, 37 and 30 in Groups 1, 2 and 3, respectively. Age at study entry (median years [range]) was 3.3 [0.9–21.2], 3.6 [1–65.9] and 6.0 [1.1–65.9] in Groups 1, 2 and 3, respectively.
Primary ITI outcomes were available in 32 patients. Negative inhibitors were achieved in 4/6 (group 1) and 10/26 (Group 2) patients. In Group 2, 6 patients were still on ITI. Median (range) FVIII ITI doses were 487.5 (198.9–729.2) and 269.4 (47.6–1228.1) IU/kg/week in Groups 1 and 2, respectively. One Group 1 and 2 Group 2 patients failed to meet all 3 ITI outcome criteria.
Of high-responder patients (titer ≥5 BU/mL) on primary ITI, 1/1 in Group 1 and 0/8 in Group 2 achieved negative inhibitors with an initial median (range) dose of 170.5 (NA) and 217.6 (101.4–1018.2) IU/kg/week, respectively. The Group 1 patient achieved complete success after 20 months of ITI.
Overall, there were 155 BEs in 43 patients. There were 32 joint bleeds of which 69% occurred in Group 3. Median (range) total ABR for patients with a minimum treatment period of ≥6 months was 0 (0–9.9), 0.4 (0–6.5) and 0.2 (0–6.1) for Groups 1, 2 and 3 respectively. Median (range) joint ABR was 0 (0–1.7) in Group 1, 0 (0–1.2) in Group 2 and 0 (0–1.5) in Group 3.
One mild ADR (rash, red papules) with emicizumab occurred without drug discontinuation. No serious ADRs or thrombotic complications were reported.
Conclusions: Negative inhibitors have been reported in ITI patients both with and without emicizumab prophylaxis. BEs occurred in all groups, with the highest proportion of joint BEs in emicizumab only group (Group 3). No serious safety concerns including thrombotic or thrombotic microangiopathy events were reported.
DISCLOSURES
Robert F. Sidonio Jr, MD,MSc: ATHN - Other (including travel support); HFA - Other (including travel support); ISTH - Other (including travel support); Takeda - Research Funding; Octapharma - Research Funding; LFB/Hema Biologics - Research Funding; HemAB - Consultancy (Includes expert testimony); Bayer - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Guardian Therapeutics - Consultancy (Includes expert testimony); Star/Incyte - Consultancy (Includes expert testimony); LFB/Hema Biologics - Consultancy (Includes expert testimony); Sanofi/Sobi - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Roche/Genentech - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony); ISTH - Membership on a Board/Advisory Committee; ATHN - Membership on a Board/Advisory Committee